Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

4(50.0%)

Phase 2

3(37.5%)

Phase 3

1(12.5%)

8Total

Phase 1(4)

Phase 2(3)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT05322720Phase 2Unknown

HR Positive, HER2 Negative Advanced Breast Cancer With Progression After Endocrine Therapy

Role: lead

NCT03600090Phase 1Completed

Phase I Study of EOC202 Plus Paclitaxel in Chinese Patients With Metastatic Breast Cancer

Role: lead

NCT03538171Phase 3Unknown

Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer

Role: lead

NCT03583125Phase 1Unknown

Study of EOC317 in Chinese Patients With Advanced Solid Tumors

Role: lead

NCT03175497Phase 1Completed

Telatinib Safety and Pharmacokinetics Study in China Patients With Advanced Solid Tumors

Role: lead

NCT03817411Phase 2Unknown

Telatinib in Combination With Capecitabine/ Oxaliplatin in 1st Line Gastric or GEJ Cancer

Role: lead

NCT02833155Phase 1Completed

Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer

Role: lead

NCT03085368Phase 2Unknown

A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin

Role: collaborator

All 8 trials loaded